I hope this message finds you healthy and thriving! 💖 Today, I'd like to dive into a critical but often overlooked aspect of heart health: Lipoprotein(a), or Lp(a).
🔎 Why Lp(a) Matters:
💡 Lp(a) is a unique lipoprotein circulating in our blood. Elevated Lp(a) significantly raises the risk of cardiovascular diseases like heart attacks and strokes.
🔬 Key Facts About Lp(a):
Lp(a) levels are primarily genetically determined 🧬, making them largely resistant to dietary and lifestyle interventions.
Promotes the buildup of artery-clogging plaque (atherosclerosis) and increases the risk of blood clots 🩸, raising your chance of cardiovascular blockages.
Individuals with elevated Lp(a) have a 2-4 times higher risk of cardiovascular events compared to those with lower levels ⚠️.
🚧 The Treatment Challenge:
Traditional cholesterol treatments (such as statins, ezetimibe, or fibrates) have minimal or no effect on lowering Lp(a). In fact, statins might slightly elevate Lp(a) levels, presenting additional challenges.
🎯 Why We've Focused on LDL ("Bad Cholesterol") and Leqvio:
Due to the limited direct treatment options for Lp(a), cardiovascular care historically targets LDL cholesterol, a well-known and manageable risk factor.
✅ Leqvio (inclisiran):
Effectively reduces LDL cholesterol by blocking a protein called PCSK9, which increases LDL receptor availability in the liver.
Provides modest Lp(a) reductions (around 20-30%)—helpful but often insufficient for significant Lp(a) elevations.
🚀 Exciting New Treatments on the Horizon:
Researchers are developing promising therapies specifically targeting Lp(a):
🔹 Pelacarsen (Antisense Oligonucleotide, ASO Therapy):
Targets the messenger RNA responsible for producing a key component of Lp(a), significantly reducing its levels by up to 80% in clinical trials.
🔸 Olpasiran (RNA Interference, RNAi Therapy):
Employs gene-silencing technology to dramatically reduce Lp(a) levels by over 90%, marking a groundbreaking advancement in treatment.
🔹 Other siRNA Therapies:
Additional small interfering RNA (siRNA) treatments are being explored with similar promising potential to substantially reduce Lp(a).
These innovative treatments represent a significant leap forward from traditional therapies, offering new hope for patients previously underserved.
🌈 What the Future Holds:
With therapies like pelacarsen and olpasiran actively undergoing clinical trials, we're nearing an era where direct and effective Lp(a) reduction is achievable. These medications are being tested not just for their ability to lower Lp(a), but also for their safety and their potential to significantly reduce cardiovascular events such as heart attacks and strokes. Soon, these could become standard treatment for patients with high Lp(a) levels.
🎯 What You Can Do Right Now:
As we await these groundbreaking treatments, it's essential to control other cardiovascular risk factors diligently:
Keep LDL cholesterol levels well-managed 📉.
Regularly monitor and manage your blood pressure and blood sugar 🍎.
Embrace healthy lifestyle changes, including quitting smoking, maintaining a healthy weight, and staying physically active 🚭🏃♂️.
📚 In Summary:
Lp(a) is a critical yet challenging cardiovascular risk factor that traditional treatments struggle to address effectively. The exciting news is that new medications specifically targeting Lp(a) are nearing clinical availability. We remain optimistic about these groundbreaking therapies and committed to safeguarding your heart health.
Thank you for staying informed! If you have questions or wish to discuss further, please feel free to reach out anytime.
Warmest regards,
Afshine Emrani, MD
Assistant Clinical Professor, UCLA
David Geffen School of Medicine
🏅 Castle-Connolly Nationwide Top Doctor (Since 2008)
🌟 Los Angeles Magazine Super Doctor (Since 2010)
🇺🇸 LA Style Magazine Top 100 Doctors in America (2024)
📬 Subscribe to my newsletter: substack.com/@afshineemrani
📖 Explore my books: